BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baker D, Pryce G, Jackson SJ, Bolton C, Giovannoni G. The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis. Mult Scler Relat Disord. 2012;1:64-75. [PMID: 25876933 DOI: 10.1016/j.msard.2011.11.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Pryce G, Riddall DR, Selwood DL, Giovannoni G, Baker D. Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids. J Neuroimmune Pharmacol 2015;10:281-92. [PMID: 25537576 DOI: 10.1007/s11481-014-9575-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 5.1] [Reference Citation Analysis]
2 Pryce G, Visintin C, Ramagopalan SV, Al-Izki S, De Faveri LE, Nuamah RA, Mein CA, Montpetit A, Hardcastle AJ, Kooij G, de Vries HE, Amor S, Thomas SA, Ledent C, Marsicano G, Lutz B, Thompson AJ, Selwood DL, Giovannoni G, Baker D. Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists. FASEB J 2014;28:117-30. [PMID: 24121462 DOI: 10.1096/fj.13-239442] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
3 Syed YY, McKeage K, Scott LJ. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis. Drugs. 2014;74:563-578. [PMID: 24671907 DOI: 10.1007/s40265-014-0197-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
4 Moreno-martet M, Feliú A, Espejo-porras F, Mecha M, Carrillo-salinas FJ, Fernández-ruiz J, Guaza C, de Lago E. The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptors. Multiple Sclerosis and Related Disorders 2015;4:505-11. [DOI: 10.1016/j.msard.2015.08.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
5 Atsmon J, Cherniakov I, Izgelov D, Hoffman A, Domb AJ, Deutsch L, Deutsch F, Heffetz D, Sacks H. PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers. Journal of Pharmaceutical Sciences 2018;107:1423-9. [DOI: 10.1016/j.xphs.2017.12.020] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 9.7] [Reference Citation Analysis]
6 Brodie JS, Di Marzo V, Guy GW. Polypharmacology Shakes Hands with Complex Aetiopathology. Trends Pharmacol Sci 2015;36:802-21. [PMID: 26434643 DOI: 10.1016/j.tips.2015.08.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
7 Nielsen S, Murnion B, Campbell G, Young H, Hall W. Cannabinoids for the treatment of spasticity. Dev Med Child Neurol 2018;61:631-8. [DOI: 10.1111/dmcn.14165] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
8 Luquiens A, Lourenco N, Benyamina A, Aubin HJ. Self-medication of achalasia with cannabis, complicated by a cannabis use disorder. World J Gastroenterol 2015;21:6381-3. [PMID: 26034374 DOI: 10.3748/wjg.v21.i20.6381] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
9 Keating GM. Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity. Drugs 2017;77:563-74. [PMID: 28293911 DOI: 10.1007/s40265-017-0720-6] [Cited by in Crossref: 43] [Cited by in F6Publishing: 30] [Article Influence: 10.8] [Reference Citation Analysis]
10 Baker D, Pryce G, Visintin C, Sisay S, Bondarenko AI, Vanessa Ho WS, Jackson SJ, Williams TE, Al-Izki S, Sevastou I, Okuyama M, Graier WF, Stevenson LA, Tanner C, Ross R, Pertwee RG, Henstridge CM, Irving AJ, Schulman J, Powell K, Baker MD, Giovannoni G, Selwood DL. Big conductance calcium-activated potassium channel openers control spasticity without sedation. Br J Pharmacol 2017;174:2662-81. [PMID: 28677901 DOI: 10.1111/bph.13889] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
11 Sisay S, Pryce G, Jackson SJ, Tanner C, Ross RA, Michael GJ, Selwood DL, Giovannoni G, Baker D. Genetic background can result in a marked or minimal effect of gene knockout (GPR55 and CB2 receptor) in experimental autoimmune encephalomyelitis models of multiple sclerosis. PLoS One 2013;8:e76907. [PMID: 24130809 DOI: 10.1371/journal.pone.0076907] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
12 Pryce G, Cabranes A, Fernández-Ruiz J, Bisogno T, Di Marzo V, Long JZ, Cravatt BF, Giovannoni G, Baker D. Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors. Mult Scler 2013;19:1896-904. [PMID: 23625705 DOI: 10.1177/1352458513485982] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
13 Baker D, Amor S. Experimental autoimmune encephalomyelitis is a good model of multiple sclerosis if used wisely. Mult Scler Relat Disord 2014;3:555-64. [PMID: 26265267 DOI: 10.1016/j.msard.2014.05.002] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 6.1] [Reference Citation Analysis]